Gao Chunpo resigns from his position as President of Keyuan Pharmaceutical, four months after stepping down as Chairman.

Source: Taishan Finance

Taishan Finance Reporter Zhao Shijie

Taishan Finance has learned that recently, Keyuan Pharmaceutical (301281.SZ) announced that Gao Chunpao has applied to resign from his position as President due to work adjustments and will no longer serve as the legal representative. After stepping down, Gao Chunpao will not hold any positions in the company. At the same time, the company appointed Wei Zhiguo as President, and Li Yanbing as Vice President and Chief Financial Officer.

The reporter found that Keyuan Pharmaceutical has undergone multiple senior personnel changes in the past year. The resignation of Gao Chunpao comes only four months after he stepped down as Chairman.

Looking back at previous changes, in March 2025, former Chairman Jiang Hongsheng resigned from his positions as director, chairman, and general manager due to work adjustments and no longer served as the company’s legal representative. Gao Chunpao succeeded him as chairman and simultaneously served as legal representative.

On December 1 of the same year, Keyuan Pharmaceutical announced that, due to personal reasons, Gao Chunpao would no longer serve as chairman or employee representative director but would remain as general manager. Li Hongfu was appointed as the new chairman and employee director.

Just three days later, Keyuan Pharmaceutical issued another announcement stating that Li Chunhua, former deputy general manager, secretary of the board, and financial officer, resigned due to personal reasons and would no longer hold other positions in the company.

The new President Wei Zhiguo also currently serves as President of Keyuan Pharmaceutical’s wholly owned subsidiary, Shandong Linuo Pharmaceutical Co., Ltd. According to his background, he was born in March 1979, holds a bachelor’s degree, an EMBA master’s degree, and is a registered safety engineer. He has previously served as President of Shanghai Huatuo Pharmaceutical Technology Development Co., Ltd., Assistant to the Chairman of Beijing Beilu Pharmaceutical Co., Ltd., and head of operations management at Sichuan Huiyu Pharmaceutical Co., Ltd.

Vice President and CFO Li Yanbing was born in January 1982, holds a master’s degree in accounting from Renmin University of China, and has CMA certification. She previously served as CFO of Yiling Wanzhou International Pharmaceutical Co., Ltd.

Data shows that Keyuan Pharmaceutical was founded in 2004 and was listed on the ChiNext Board of the Shenzhen Stock Exchange in April 2023. It is a leading enterprise in the domestic chemical raw material drug segment. The company focuses on the research, development, production, and sales of chemical raw materials and formulations, covering areas such as hypoglycemics, anesthetics, and cardiovascular drugs.

In terms of ownership structure, the controlling shareholder of Keyuan Pharmaceutical is Linuo Investment Holding Group Co., Ltd., which is affiliated with Linuo Group Co., Ltd. (referred to as “Linuo Group”).

Linuo Group was established in 1994, headquartered in Jinan. Its core industries are health, new energy, and new materials. It is among China’s top 500 manufacturing companies and the top 100 private enterprises in Shandong Province, owning listed companies Linuo Pharmaceutical (301188.SZ) and Keyuan Pharmaceutical. The actual controller of the group is founder Gao Yuan-kun.

Special statement: The above content only represents the author’s personal views or positions and does not reflect the views or positions of Sina Finance Headlines. If you need to contact Sina Finance Headlines regarding issues related to the content, copyright, or other matters, please do so within 30 days of the publication date.